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Abstract
Several population studies relate exposure to high levels of arsenic with an increased incidence of 
ischemic heart disease and cardiovascular mortality. An association has been shown between exposure 
to high levels of arsenic and cardiovascular risk factors such as hypertension and diabetes mellitus, and 
vascular damage such as subclinical carotid atherosclerosis. The mechanisms underlying these 
phenomena are currently being studied and appear to indicate an alteration of vascular function. 
However, the effects of low levels of exposure to arsenic and their potential detrimental cardiovascular 
effect are less explored. The article provides an overview of the pathophysiologic mechanisms linking 
low-level arsenic exposure to the occurrence of cardiovascular disease and its complications, and some 
potential preventive strategies to implement.
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Arsenic (As) is a natural element of the earth’s crust whose toxicity has been known for centuries. 
Adverse effects depend on dose, duration and frequency of exposure, and can range from neurological 
and respiratory damage to the onset of cancers of the skin, lung and bladder (Brunton LL 2011; Longo 
DL 2012): the International Agency for Research on Cancer has classified inorganic As as a group 1 
human carcinogen (WHO-IARC 2012). Occupational exposure and intentional poisoning are well-
known sources of acute toxicity, whereas lower-level long-standing exposures require a broad range of 
expertise for As detection and the study of environmental fate and mechanisms of human toxicity. The 
main cause of chronic intoxication for the general population is ingestion of drinking water drilled in 
deposits contaminated with this metalloid, occurring mainly in developing countries, but also to a lesser
extent in the Western world (Lisabeth et al. 2010; Medrano et al. 2010). The World Health 
Organization and most national legislations have set a limit of 10 g/L of As in drinking water, 
corresponding to the reliable detection threshold using current methods, while some countries 
(especially developing countries) still maintain a threshold of 50 g/L as recommended by WHO 
before 1993. 
The Joint FAO/WHO Expert Committee on Food Additives (JECFA) set a Provisional Tolerable Intake
(PTWI) for inorganic As at 2.1 g/Kg/day or 15 g/Kg/week (JECFA 1989). The European Food 
Safety Authority Panel on Contaminants in the Food Chain (EFSA-CONTAM) noted that after this 
PTWI was established, new data showed that inorganic As causes cancer of the lung and urinary tract 
in addition to skin, and a range of adverse effects have been reported at exposures lower than those 
reviewed by the JECFA, concluding that the PTWI of 15 μg/Kg was not appropriate. In 2010 the 
JECFA withdrew the PTWI (JECFA 2011). The main adverse effects reported by the EFSA-CONTAM
Panel associated with long-term ingestion of inorganic As in humans were skin lesions, cancer, 
developmental toxicity, neurotoxicity, cardiovascular (CV) disease, abnormal glucose metabolism and 
diabetes. On the other hand, evidence of CV disease and diabetes in areas with relatively low levels of 
inorganic As exposure was evaluated as inconclusive (EFSA-CONTAM 2009).
High levels of As exposure in drinking water have been related to increased risk of CV disease. Since 
this is a major cause of death worldwide, and most of the world’s population resides in developing 
countries where the incidence of CV disease is rising, even a modest increase in risk due to As in 
groundwater might have substantial impact on morbidity and mortality.
The fate of As in the human body
The metalloid As is a natural environmental contaminant. It is present in organic and inorganic form, 3
and in different valence or oxidation states – mainly the trivalent (III) and pentavalent (V). The most 
toxicologically potent As compounds are in the trivalent oxidation state. Organic arsenicals in the 
pentavalent oxidation state – such as those used as pesticides, even today – are much less toxic than 
inorganic ones, because unlike inorganic As they are not readily taken up by cells, and undergo limited 
metabolism (Cohen et al. 2006; Hughes et al. 2011); concern regarding these compounds is due to their 
progressive breakdown to inorganic As in the environment. As is ubiquitous; diet is the main source of 
total As for humans, but the organic compounds normally present in food, especially in fish and 
seafood, are considered non-toxic or of low toxicity. Populations living in coastal areas have on average 
higher urinary excretion of As than those living inland, without this in itself turning out in toxicity
(Delgado-Andrade et al. 2003; EFSA-CONTAM 2009; JECFA 2011; WHO-IARC 2012). Total urinary 
As is an unreliable marker of exposure to inorganic As, the most toxic form, so studies often adjust this 
measurement for seafood consumption (Navas-Acien et al. 2008; Kim and Lee 2011; Moon et al. 2012).
Soil, air, and absorption through the skin are a minor source of As for the general population, but may 
be important in professional exposure.
Conversely, As found in water is almost entirely inorganic, and drinking water accounts for most 
exposure to this form. In water As is not in its elemental form, which is insoluble, but as arsenate 
(pentavalent) in surface water, while arsenite (trivalent) is more prevalent in deep anoxic wells (Flora 
2011; WHO-IARC 2012). Metabolization in the human body is not completely understood, but the main
step is methylation, primarily in the liver, with or without the involvement of glutathione (GSH)
(Watanabe and Hirano 2012); most excretion in the urine is in the form of dimethyl, a smaller part as 
methyl, while about a quarter is excreted as inorganic (Vahter 2000). While methylation is a 
detoxification process (Huang et al. 2009), some of the intermediate metabolites, particularly those with 
trivalent As, could mediate some of the toxic and carcinogenetic effects of As.
The precise mode of action of As toxicity is even less well-known. Several modes of action, possibly 
interrelated, have been proposed: interaction with sulfur and binding to sulfhydryl groups on proteins 
and enzymes; substitution of arsenate for phosphate, since As and phosphorus both belong to group 15 
of the periodic table and share physiochemical properties, cutting off ATP formation in particular; 
substitution for zinc in zinc fingers; genotoxic action, potentiating the mutagen action of other 
compounds but also inhibiting DNA enzymatic repair and altering DNA methylation; and alteration of 
cellular signal transduction (Hughes et al. 2011; Flora 2011). The formation of reactive oxygen species 
(ROS), also occurring at concentrations that are not directly cytotoxic (Barchowsky et al. 1996), could 
be the pathogenic mechanism for the observed CV effects. 4
As and CV disease
Several epidemiological studies in different countries have found a relationship between exposure to 
high levels of As – as high as > 50 μg/L in drinking water, but the limits used to define “high”, 
“moderate” or “low” referring to non-professional exposure vary widely – and CV disease. The 
relationship is particularly evident for peripheral arterial disease (“blackfoot disease” is a form of PAD 
endemic to areas of Taiwan with extremely high levels of As in drinking water (Tseng 1977)) and 
coronary heart disease, while the association with stroke is less strong and of borderline significance
(Lisabeth et al. 2010; Moon et al. 2012). The studies globally show a temporal sequence between time 
of exposure and onset of disease, have yielded consistent results in different countries and populations, 
show a dose-response relation, and show decreased incidence of disease where reduced exposure has 
been implemented (Chang et al. 2004; Yuan et al. 2007). The association between As and CV disease is 
at least partly independent of traditional risk factors; prospective studies do confirm the association
(Chen et al. 2011b) and various biological mechanisms for CV toxicity have been investigated; all this is
enough to define a causal relationship, i.e., a high level of As exposure is an established risk factor for 
CV disease (Saposnik 2010; Moon et al. 2012).
Less is known about the CV effects of exposure to lower As levels, closer to the WHO threshold, which 
interests a much larger population worldwide. Results are conflicting; at these levels, the magnitude of 
the effect is expected to be smaller, and methodological limitations – mainly the difficulty of assessing 
actual and cumulative individual exposure, but also the distinction between organic and inorganic As, 
and outcome measures with the potential confounders – may have played a role in the non-significance 
of most statistical associations performed so far. 
As in the CV continuum
As has been associated in a dose-dependent manner with high blood pressure (Wang et al. 2011; 
Abhyankar et al. 2012), even at low levels of exposure (Zhang et al. 2012a), and with renal dysfunction
(Chen et al. 2011a) and proteinuria (Chen et al. 2011c). The association with diabetes has been limited 
to sufficient evidence for high levels (Maull et al. 2012), while some recent data (Jovanovic et al. 2012) 
conducted with more precise exposure measurements assessing the relation with glucose metabolism
(Del Razo et al. 2011) suggest an association even at lower levels (Huang et al. 2011; Maull et al. 2012).
The pathophysiological mechanism could be a direct toxic effect on beta-cells, interaction with cellular 
signaling, or enzyme inhibition in beta-cells or in peripheral tissues (Huang et al. 2011). Consistent with5
the association with risk factors and CV disease, an association has also been found between As 
exposure and atherosclerosis (Wang et al. 2002; Wang et al. 2010; Hsieh et al. 2011), and confirmed in 
experimental animal studies (Bunderson et al. 2004; Srivastava et al. 2009; Lemaire et al. 2011).
Endothelial dysfunction: the link between As and CV disease?
Oxidative stress is an established and widely studied mechanism of As toxicity. ROS are formed both in 
vivo and in vitro in the presence of As. They include superoxide anion, hydroxyl radical, hydrogen 
peroxide, reactive nitrogen species, and As-centered and As peroxyl radicals (Bao and Shi 2010b; 
Hughes et al. 2011; Flora 2011). The mechanisms of ROS formation by As are not completely clear: 
they may be produced during oxidation of arsenite (III) to arsenate (V) during metabolization, by 
stimulation of the enzymes NADH or NADPH oxidase (Smith et al. 2001), and NOX (States et al. 
2009), or by mobilization of free iron from ferritin (Shi et al. 2004; Flora 2011; Jomova et al. 2011).
Nitric oxide (NO) is one of the main mediators released from the endothelium. It has vasodilatory and 
anti-inflammatory properties, and inhibits platelet adhesion and aggregation, as well as smooth muscle 
cell proliferation and migration. ROS inactivate NO and reduce its bioavailability in the vascular 
endothelium. In addition to the direct action of ROS on NO, As inhibits endothelial NO synthetasis 
(eNOS) (Fig. 1) (Lee et al. 2003; Tsou et al. 2005; Li et al. 2007), it depletes GSH – one of the main 
antioxidant ROS scavengers – and inhibits redox enzymes (catalase, glutathione peroxidase and 
reductase, thioredoxin reductase, superoxide dysmutase). The disruption of antioxidant defense 
mechanisms and the blocking of new NO formation further decrease NO bioavailability and increase 
endothelial dysfunction (Pi et al. 2000). It is notable that acute exposure or low doses do actually induce 
redox enzymes, indirectly confirming their role in As detoxification (Shi et al. 2004; Flora 2011). 
Consistently with the oxidative stress frame, several antioxidants have shown, in vivo or in vitro, a 
protective effect against As-induced toxicity. These include N-acetylcysteine (Bao and Shi 2010a), 
alpha-lipoic acid, vitamin C and E, taurine, quercetin (Ghosh et al. 2011), some plant extracts including 
garlic (Balakumar and Kaur 2009; Biswas et al. 2010; Flora 2011), and resveratrol (Zhao et al. 2008b; 
Zhang et al. 2012b).
When NO concentrations are reduced, the endothelial surface becomes more prone to atherosclerosis, 
cell adhesion and thrombosis, a condition known as endothelial dysfunction, common to all major CV 
risk factors (aging, hypertension, diabetes, dyslipidemia, etc.) (Deanfield et al. 2007). One of the 
mechanisms by which As induces endothelial dysfunction is by exaggerating calcium influx in cells
(Suriyo et al. 2012). Exposure to As augments endothelial permeability through increased VEGF 6
expression (Bao and Shi 2010a) and reduces proteoglycan synthesis in endothelial cells (Fujiwara et al. 
2005); individuals drinking water contaminated with As show dose-dependent expression of plasma 
levels of cell adhesion molecules (CAM), i.e., a pro-atherosclerotic endothelium (Chen et al. 2007). 
While it is known that As enhances oxidative stress, and that oxidative stress produces endothelial 
dysfunction, the direct link between exposure to As and endothelial dysfunction in humans has not been 
investigated extensively. There are no published studies on As and in vivo endothelial function, either in
small vessels (venous plethysmography) (Joannides et al. 2006) or conduit vessels (flow-mediated 
dilation) (Deanfield et al. 2007). 
Other mechanisms of CV damage
Endothelial dysfunction characterizes arterial hypertension, and pharmacological blockade of eNOS by 
L-NMMA raises blood pressure (Owlya et al. 1997), so diminished NO availability is a plausible 
mechanism to link As with hypertension (Hsueh et al. 2005). Moreover, As decreases in vitro vascular 
relaxation capability, both endothelium-dependent and endothelium-independent, directly acting on the 
smooth muscle cells (Lee et al. 2003), while it potentiates response to vasoconstrictors through myosin 
light chain phosphorylation and Ca++ sensitization/inflow (Lee et al. 2005; Li et al. 2010; Lim et al. 
2011). Interaction with arachidonic acid biotransformation, influencing vasoconstriction and relaxation, 
may be another mechanism (Bunderson et al. 2004). Renal damage may be involved in raising blood 
pressure (Chen et al. 2011c; Hsueh et al. 2009), but the causal relationship with this association remains 
to be clarified. 
As exposure in a wide range of levels is consistently associated with QT prolongation – a risk factor for 
arrhythmia and sudden cardiac death – torsade de pointes (Ficker et al. 2004; Mumford et al. 2007; 
Mordukhovich et al. 2009; Wang et al. 2009), and increased QT dispersion (Wang et al. 2010). As may 
act on QT by increasing cardiac calcium currents (Ficker et al. 2004), but no protective effect of 
calcium-antagonists has been found (Mordukhovich et al. 2009) and there are conflicting data on 
verapamil enhancing or reducing As cardiotoxicity (Zhao et al. 2008a; Luong and Rabkin 2009).
Through the abovementioned mechanisms, As also exerts its direct cytotoxic effects on cardiomyocytes,
inducing apoptosis or necrosis (Zhao et al. 2008a; Luong and Rabkin 2009); moreover, the myocardium 
appears to be a sensitive target tissue for As (Roman et al. 2011). However, population data are scarce, 
while cardiotoxicity of As2O3 as a chemotherapeutic drug is well-known, and is more marked in Afro-
Americans, probably due to genetic susceptibility (Patel et al. 2006). Specific effects of As on the heart 
could explain the disproportionate increase in CV events compared to stroke despite the known effect on7
blood pressure (Zierold et al. 2004; Lisabeth et al. 2010). Although there appear to be no studies 
regarding a relationship between heart failure or cardiomyopathy and As, there are hints of a synergistic 
toxic effect of As and alcohol on the heart (Navas-Acien et al. 2006; Bao and Shi 2010b).
Polymorphisms in the genes of enzymes involved in As metabolism, especially As methyltransferase, 
and in redox enzymes can modulate As toxicity and its CV effects (Vahter 2000; Hsueh et al. 2005; 
States et al. 2009; Hsieh et al. 2011; Hughes et al. 2011)
Reduced synthesis of extracellular matrix and damage to vascular smooth muscle cells are other 
mechanisms that could promote atherosclerotic plaque formation and instability (Hays et al. 2008; Li et 
al. 2010), while oxidation of lipids would make them more prone to be internalized in the vessel wall
(Srivastava et al. 2009). As appears to enhance platelet aggregation (Lee et al. 2002), possibly by 
exposing phosphatidylserine (Bae et al. 2009) though studies are conflicting (Lin et al. 2010), and 
reduces endothelial fibrinolytic activity by reducing t-PA and increasing PAI-1 level and activity (Jiang 
et al. 2002), and reduces synthesis of proteoglycans such as heparan sulfate (Fujiwara et al. 2005). The 
activity of As on coagulation and platelets could aggravate thrombosis when the atherosclerotic plaque 
ruptures (Fig. 2).
CV toxicity of As: diagnosis and therapy 
CV toxicity due to As exposure can be suspected based on personal history. Professional exposure is a 
concern for people working in mines, the wood industry, coal-fired power plants, ore smelting, battery 
assembly, and electronics. Intentional poisoning was considered a “perfect crime” in the past since As is
odorless and tasteless and symptoms of acute intoxication are quite aspecific, but its use has become 
rare since As is now detectable in fluids and tissues (Hughes et al. 2011). Contamination of drinking 
water is usually well-known in particular areas. The patient should be carefully questioned and 
examined for other As-associated diseases, such as skin lesions and cancers. Hints from clinical history 
and examination must be confirmed by evidence of As levels in body fluids and tissues indicative of 
exposure (Das and Sengupta 2008; Marchiset-Ferlay et al. 2012). Since As is metabolized from the 
blood within a period of hours, blood As levels – normally < 1 g/l – are not a good indicator of long-
term exposure, and they are only partially correlated with As in drinking water. The majority of 
absorbed As is excreted in the urine, normally within 1-2 days, so that urinary As is considered a 
reliable marker of recent exposure (Jomova et al. 2011). However, as previously mentioned not all 
forms of As are (equally) toxic, so total urinary As should be considered only a screening test, or 
suitable for population studies or continuous professional exposure. Distinguishing organic from 8
inorganic forms, and between oxidation states, requires more complex methods such as chromatographic
techniques or spectrometry, and special care in managing the sample – adjusting for seafood 
consumption, the major source of organic As, is neither reliable nor plausible on a routine basis at the 
individual level. Studying As in toenails and hair, where trivalent As binds with sulfhydryl groups in 
keratin, provides information on a more long-term exposure. As species are more stable in these 
samples, and most of the As is inorganic; on the other hand, the correlation between toenail As and 
exposure to inorganic As is poor (Hinwood et al. 2003; Slotnick and Nriagu 2006). Variable growth rate
of skin appendages could be another confounding factor (Das and Sengupta 2008; Marchiset-Ferlay et 
al. 2012).
There are no guidelines or consensus statements that tell the clinical cardiologist when to screen for As 
exposure, but aside from confirmation of exposure suspected on the basis of history or environment, a 
reasonable approach might be to search for As in patients when arrhythmias or CV events occur without
obvious cause or in absence of traditional risk factors.
Patients diagnosed with As poisoning should be promptly removed from sources of the metalloid and 
provided with supportive measures and specific care for the diseases developed, along with treatment of 
symptoms and correction of nutritional deficits (States et al. 2009) and electrolyte imbalance, which 
increases the risk for arrhythmias. The most effective specific treatment for arsenicosis is chelation 
therapy (Brunton LL 2011; Longo DL 2012); however, it is limited to life-threatening conditions due to 
its potentially severe side effects. Most of the effects of antioxidants have been tested either in vitro, on 
animals, or (in humans) on soft endpoints (Biswas et al. 2010) but there is some indication of their 
usefulness as adjunctive therapy during chelation, especially for N-acetylcysteine (Flora et al. 2007).
Conclusions
Several studies suggest CV effects of As exposure at low-to-moderate levels. These effects may 
translate into a higher CV mortality; however, studies on mortality from CV disease have been 
inconsistent. Although the mechanisms through which As can cause atherosclerotic lesions and their 
complications have been explored, individual risks from environmental pollution remain to be 
established. Many factors make the assessment of such a relationship quite difficult, such as the means 
of measurement, confounding factors from conventional risk factors for CV disease, and the variability 
of threshold allowed by individual countries for As pollution. It is time to move from population to 
individual risk assessment in order to profile the real impact of As exposure at low doses through 
imaging biomarkers of atherosclerosis. More prospective studies designed to assess doses (thresholds) 9
and risks and individual susceptibility through genetic testing are needed to explore the relationship 
between As exposure and the occurrence of CV disease and its complications. 
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Legend to figures
Fig. 1. Arsenic and endothelial dysfunction
ATG: angiotensinogen, AT: angiotensin, ACE: angiotensin converting enzyme, ET: endothelin, COX: 
cyclooxygenase, PG: prostaglandin, TX: tromboxane, NADPH: nicotinamide dinucleotide phosphate, 
eNOS: endothelial nitric oxide synthase, NO: nitric oxide, cGMP: cyclic guanosine monophosphate, 
EDHF: endothelium-derived hyperpolarizing factors 
Fig. 2. Arsenic and mechanisms of CV damage
SMC: smooth muscle cells, GSH: glutathione, t-PA: tissue plasminogen activator, PAI-1: plasminogen 
activator inhibitor type 1
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